Following closure of an oversubscribed first round, AxioMed opened a US $10MM round of funding to support operations and ex-U.S. sales.
In 1Q17, the company completed collection and analysis of 2-year follow-up data in its U.S. Investigational Device Exemption (IDE) clinical study of its viscoelastic lumbar disc. AxioMed expects 1Q18 CE Mark approval for its lateral disc, and is pursuing a multi-level cervical IDEÂ in the U.S.
Following closure of an oversubscribed first round, AxioMed opened a US $10MM round of funding to support operations and ex-U.S. sales.
In 1Q17, the company completed collection and analysis of 2-year follow-up data in its U.S. Investigational Device Exemption (IDE) clinical study of its viscoelastic lumbar disc....
Following closure of an oversubscribed first round, AxioMed opened a US $10MM round of funding to support operations and ex-U.S. sales.
In 1Q17, the company completed collection and analysis of 2-year follow-up data in its U.S. Investigational Device Exemption (IDE) clinical study of its viscoelastic lumbar disc. AxioMed expects 1Q18 CE Mark approval for its lateral disc, and is pursuing a multi-level cervical IDEÂ in the U.S.
Copy to clipboard 
